Physician profile
Nathan Hoff
NPI 1174104624
$1,111.85
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2023: $438 · 2024: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $267.47 | 2023-2024 | Uzedy, Austedo Xr |
| Alkermes, INC. | $237.84 | 2021-2024 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $163.26 | 2021-2023 | Invega Sustenna |
| Abbvie INC. | $153.70 | 2023-2024 | |
| Axsome Therapeutics, INC. | $113.10 | 2023-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $50.84 | 2024 | Rexulti |
| Eisai INC. | $39.17 | 2024 | |
| Alexion Pharmaceuticals, INC. | $25.64 | 2023 | Ultomiris |
| Novo Nordisk INC | $17.02 | 2023 | Rybelsus, Ozempic |
| Pfizer INC. | $16.57 | 2023 | |
| Lundbeck LLC | $14.03 | 2024 | Rexulti |
| Indivior INC. | $13.21 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.